The pathophysiological role of renal dopaminergic activity in patients with essential hypertension.
To evaluate the role of the renal dopaminergic system on renal water-sodium metabolism patients with essential hypertension (EHT), urinary excretion of dopamine, urinary excretion of sodium (UNaV) and fractional excretion of sodium (FENa) were all investigated before and after the administration of dopamine (3 micrograms/kg/min, intravenous infusion for 60 minutes), dopamine antagonist, metoclopramide (8 mg/m2 BSA, intravenous injection) or mild sodium loading in both normotensive subjects and benign EHT. In the basal values, no significant difference in urinary excretion of free (u-fDA), conjugated (u-cDA) or total dopamine (u-tDA) was found between normotensives and hypertensives. However, low renin EHT showed a pronounced reduction in u-fDA compared with normotensis subject and (NT) normal renin EHT. In this study, a significant reduction of u-cDA and of u-tDA was also found in those patients with low renin essential hypertension. In the normotensive and essential hypertensive groups UNaV or FENa showed a positive correlation with u-fDA (measured simultaneously), but not with u-tDA or u-cDA. The regression line between u-fDA and UNaV or FENa in EHT was shifted towards a lower u-fDA level than in NT. UNaV and FENa were increased by dopamine infusion and were decreased by metoclopramide injection in both NT and EHT. Changes of UNaV and FENa following dopamine or metoclopramide, showed a negative correlation with u-fDA measured immediately before the administration of these drugs. The enhanced natriuretic response to infused dopamine and the attenuated antinatriuretic response to injected metoclopramide were significant in low renin EHT, when compared with NT or normal renin EHT patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Iimura
O
O
Second Department of Internal Medicine, Sapporo Medical College, Japan.
Yamaji
I
I
Kikuchi
K
K
Shibata
S
S
Nishimura
M
M
Nozawa
A
A
Aoki
K
K
Hasegawa
T
T
Kobayakawa
H
H
Komura
H
H
D000328:Adult; D004298:Dopamine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D018492:Dopamine Antagonists; D005260:Female; D006801:Humans; D006973:Hypertension / Q000652:urine*; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage / Q000493:pharmacokinetics; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects*; D012083:Renin / Q000652:urine; D012964:Sodium / Q000652:urine; D012982:Sodium, Dietary / Q000493:pharmacokinetics
D018492:Dopamine Antagonists; D012982:Sodium, Dietary; D012964:Sodium; D012083:Renin; D008787:Metoclopramide; D004298:Dopamine